Arbutus Biopharma Corp  

(Public, NASDAQ:ABUS)   Watch this stock  
Find more results for NASDAQ:TKMR
2.90
-0.23 (-7.35%)
After Hours: 2.90 0.00 (0.00%)
Feb 8, 4:00PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.86 - 3.27
52 week 2.86 - 23.94
Open 3.12
Vol / Avg. 0.00/303,883.00
Mkt cap 156.26M
P/E     -
Div/yield     -
EPS -1.52
Shares 54.57M
Beta 1.09
Inst. own 65%
Mar 10, 2016
Q4 2015 Arbutus Biopharma Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Feb 23, 2016
Arbutus Biopharma Corp at RBC Capital Markets Healthcare Conference Add to calendar
Feb 11, 2016
Arbutus Biopharma Corp at Leerink Partners Global Healthcare Conference - 12:00PM EST - Add to calendar
Nov 18, 2015
Arbutus Biopharma Corp at Stifel Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -712.96% -259.73%
Operating margin -1430.21% -223.59%
EBITD margin - -216.97%
Return on average assets -15.54% -40.90%
Return on average equity -20.35% -52.76%
Employees 85 -
CDP Score - -

Address

100-8900 Glenlyon Parkway
BURNABY, BC V5J 5J8
Canada
+1-604-4193200 (Phone)
+1-604-4193201 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Arbutus Biopharma Corp, formerly Tekmira Pharmaceuticals Corporation, is a Canada-based biopharmaceutical company focused on discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). The Company seeks to effect a cure by targeting the three pillars necessary to develop a curative regimen for HBV. This includes suppressing HBV replication within liver cells, stimulating and reactivating the body’s immune system so that it can mount an effective defense against the virus and eliminating the reservoir of viral genomic material known as covalently closed circular DNA, or cccDNA, that is the source of HBV persistence.

Officers and directors

Vivek Ramaswamy Chairman of the Board
Age: 29
Bio & Compensation  - Reuters
Mark J. Murray Ph.D. President, Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Bruce G. Cousins Chief Financial Officer, Executive Vice President
Age: 54
Bio & Compensation  - Reuters
Patrick T. Higgins Chief Operating Officer
Age: 57
Bio & Compensation  - Reuters
Michael J. Abrams Ph.D. Executive Vice President and Chief Discovery Officer
Age: 58
Bio & Compensation  - Reuters
Adam D. Cutler Senior Vice President - Corporate Affairs
Bio & Compensation  - Reuters
Mark Kowalski M.D., Ph.D. Chief Medical Officer, Senior Vice President
Age: 60
Bio & Compensation  - Reuters
Michael Joseph Sofia Chief Scientific Officer
Bio & Compensation  - Reuters
Bruce Dorsey Vice President - Chemistry
Bio & Compensation  - Reuters
Rene Cornelis Rijnbrand Vice President - Biology
Bio & Compensation  - Reuters